In the cotreatment model, giving memantine concomitantly during the paclitaxel treatment led to a potentially better suppression of peripheral TNF-α  and IL-1β  and tissue TNF-α  expression, thus leading to a better reversal of mood symptoms and prevention of depression-like behavior. Here, IL1B is linked to depressive disorder.